

 참고 문헌

1. Mulders TM, Dieben TO. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. *Fertility and sterility* 2001;75:865-70
2. Pierson RA, Archer DF, Moreau M, Shangold GA, Fisher AC, Creasy GW, et al. Ortho Evra™/Evra™ versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error. *Fertility and Sterility* 2003;80:34-42
3. Ball M, Ashwell E, Gillmer M. Progestagen-only oral contraceptives: comparison of the metabolic effects of levonorgestrel and norethisterone. *Contraception* 1991;44:223-33
4. Vessey MP, Lawless M, Yeates D, McPherson K. Progestogen-only oral contraception. Findings in a large prospective study with special reference to effectiveness. *Br J Fam Plann* 1985;10:117-21
5. Organization WH. Progestogen-only contraceptives during lactation: I. Infant growth. *Contraception* 1994;50:35-53
6. Organization WH, Task Force on Oral Contraceptives. Effects of hormonal contraceptives on milk volume and infant growth. *Contraception* 1984;30:505-21
7. Cramer DW, Goldman MB, Schiff I, Belisle S, Albrecht B, Stadel B, et al. The relationship of tubal infertility to barrier method and oral contraceptive use. *Jama* 1987;257:2446-50
8. Rosenberg M, Davidson AJ, Chen J-H, Judson FN, Douglas JM. Barrier contraceptives and sexually transmitted diseases in women: a comparison of female-dependent methods and condoms. *American Journal of Public Health* 1992;82:669-74
9. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. *The Lancet* 2002;360:971-7
10. Richardson BA, Lavreys L, Martin Jr HL, Stevens CE, Nguni E, Mandaliya K, et al. Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial. *Sexually transmitted diseases* 2001;28:394-400
11. Harper CC, Ellertson CE. The emergency contraceptive pill: a survey of knowledge and attitudes among students at Princeton University. *American journal of obstetrics and gynecology* 1995;173:1438-45
12. Vasilakis C, Jick SS, Jick H. The risk of venous thromboembolism in users of postcoital contraceptive pills. *Contraception* 1999;59:79-83
13. Ho P, Kwan M. A prospective randomized comparison of levonorgestrel with the Yuzpe regimen in post-coital contraception. *Human Reproduction* 1993;8:389-92
14. Grimes D, Von Hertzen H, Piaggio G, Van Look P, Peregoudov S, Vucurevic M, et al. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Task Force on Postovulatory Methods of Fertility Regulation. *Lancet (London, England)* 1998;352:428-33
15. Young DC, Wiehle RD, Joshi SG, Poindexter 3rd A. Emergency contraception alters progesterone-associated endometrial protein in serum and uterine luminal fluid. *Obstetrics and gynecology* 1994;84:266-71
16. Swahn ML, Westlund P, Johannisson E, Bygdeman M. Effect of post-coital contraceptive methods on the endometrium and the menstrual cycle. *Acta obstetrica et gynecologica Scandinavica* 1996;75:738-44
17. Ortiz ME, Ortiz R, Fuentes M, Parraguez V, Croxatto HB. Post-coital administration of levonorgestrel does not interfere with post-fertilization events in the new-world monkey *Cebus apella*. *Human reproduction* 2004;19:1352-6
18. Glasier A. Emergency postcoital contraception. *New England*

- Journal of Medicine 1997;337:1058-64
19. Glasier A, Thong K, Dewar M, Mackie M, Baird DT. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception. *New England Journal of Medicine* 1992;327:1041-4
 20. Von Hertzen H, Piaggio G, Peregoudov A, Ding J, Chen J, Song S, et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. *The Lancet* 2002;360:1803-10
 21. Creinin MD, Schlaff W, Archer DF, Wan L, Frezieres R, Thomas M, et al. Progesterone receptor modulator for emergency contraception: a randomized controlled trial. *Obstetrics and gynecology* 2006;108:1089
 22. Fasoli M, Parazzini F, Cecchetti G, La Vecchia C. Post-coital contraception: an overview of published studies. *Contraception* 1989;39:459-68
 23. Lichter ED, Laff SP, Friedman EA. Value of routine dilation and curettage at the time of interval sterilization. *Obstetrics and gynecology* 1986;67:763-5
 24. Hankinson SE, Hunter DJ, Colditz GA, Willett WC, Stampfer MJ, Rosner B, et al. Tubal Ligation, Hysterectomy, and Risk of Ovarian Cancer: A Prospective Study. *Obstetrical & Gynecological Survey* 1994;49:326-8
 25. Miracle-McMahill HL, Calle EE, Kosinski AS, Rodriguez C, Wingo PA, Thun MJ, et al. Tubal ligation and fatal ovarian cancer in a large prospective cohort study. *American journal of epidemiology* 1997;145:349-57
 26. Powell CB, Alabaster A, Simmons S, Garcia C, Martin M, McBride-Allen S, et al. Salpingectomy for sterilization: change in practice in a large integrated health care system, 2011–2016. *Obstetrics & Gynecology* 2017;130:961-7
 27. Castellano T, Zerden M, Marsh L, Boggess K. Risks and benefits of salpingectomy at the time of sterilization. *Obstetrical & gynecological survey* 2017;72:663-8
 28. Peterson HB, Xia Z, Hughesa JM, Wilcox LS, Tylora LR, Trussell J, et al. The risk of pregnancy after tubal sterilization: findings from the US Collaborative Review of Sterilization. *American journal of obstetrics and gynecology* 1996;174:1161-70
 29. Tylor LR, Peterson HB. Higher Hysterectomy Risk for Sterilized than Nonsterilized Women: Findings from the US Collaborative Review of Sterilization. *Obstetrics & Gynecology* 1998;91:241-6